UCB PHARMA AS
Score · fiscal year 2025
45of 100
How to read this: the company is ahead of 39 % of medium-sized companies in the same sector in 2025. What does this mean?
Rank: 23,328 of 38,670 · Handel
Profile
Beaver · Builder
Lower profitability, lower solidity
Position against comparable companies in 2025, not a verdict on the company. Based on profitability 40 and solidity 35 out of 100 among medium-sized companies in the same sector in 2025. Methodology
Against the sector
UCB PHARMA AS is 4 points below the median for medium-sized companies in the same sector in 2025.
Median score 49 among 2,198 companies.
Against medium-sized companies in the same sector in 2025: operating margin 3.3% (median 3.2%) and equity ratio 24.8% (median 32.6%).
The numbers behind the score
| Measure | Company | Median |
|---|---|---|
| Operating revenue | 263 MNOK | 173 MNOK |
| Operating margin | 3.3% | 3.2% |
| Profit margin | 1.9% | 3.2% |
| Return on assets | 6.0% | 11.6% |
| Equity ratio | 24.8% | 32.6% |
| Debt-to-equity | 3.04 | 2.03 |
| Current ratio | 1.33 | 1.38 |
| Revenue growth | 5.9% | 6.8% |
| Revenue per employee | 52.68 MNOK | 6.45 MNOK |
The median and “ahead of” refer to medium-sized companies in the same sector in 2025. The bar shows the share of companies the figure is ahead of.
With an index of 45, UCB PHARMA AS does better than 39% of medium-sized companies in the same sector (2,203 companies) in 2025.
Score 2023–2025
- UCB PHARMA AS
- Median: medium-sized companies in the same sector
UCB PHARMA AS has a score of 45 for 2025, rank 23,328 of 38,670 in the sector.
Strongest: Consistency: percentile 68 against peers.
Weakest: Solidity: percentile 35 against peers, equity ratio 24.8% against a median of 32.6%.
Worth a closer look
- What lies behind weak solidity, and will it last?
Written by fixed rules from the figures. Describes the figures, does not explain causes. Not investment or financial advice. How the summary is made
What the numbers say
UCB PHARMA AS had an operating margin of 3.3% and an equity ratio of 24.8% in 2025, and ranks 23,328 of 38,670 in Handel.
No large changes in the key figures from 2024 to 2025.
This text is generated automatically from the 2025 accounts.
Three simple methods
The methods give between 40 MNOK and 79 MNOK.
| Method | Multiple | Estimate |
|---|---|---|
| P/E | 10.0 | 40 MNOK |
| EV/EBIT | 8.0 | 79 MNOK |
| P/B | 1.0 | 41 MNOK |
A mechanical estimate from public accounts, not advice. Mechanical estimate from public accounts with fixed multiples. Not a valuation and not advice to buy or sell. The multiples are provisional default values and must be adjusted per sector before the figures are used for anything. See the calculation
Worth a closer look
No rules were triggered for this year.
Indications based on the latest annual accounts from open data. Not investment or financial advice.
Financial costs were 4.0% of the debt in 2025. The policy rate averaged 4.30 % the same year. This is a plain description of what the debt cost, not a model of interest sensitivity.
Data quality
No anomalies found in the figures.
Scenario analysis: the sector's weakest year
We have no accounts for 2017, the sector's weakest year, for this company.
The sector's weakest year was 2017, with a median operating margin of −65.6%. Based on the 11 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology
What the score is made of
| Profitability | 40 | weight 30% |
|---|---|---|
| Solidity | 35 | weight 25% |
| Liquidity | 47 | weight 15% |
| Growth | 46 | weight 15% |
| Consistency | 68 | weight 15% |
Durability: 45 (average over 3 years)
Index version 2. Data completeness 100%: the share of the weights that had data.
Questions and answers
How profitable is UCB PHARMA AS?
The operating margin was 3.3% in 2025, against a median of 3.2% among medium-sized companies in the same sector. Return on assets was 6.0%.
How solid is UCB PHARMA AS?
The equity ratio was 24.8% in 2025 (median 32.6%). Debt-to-equity was 3.04 (median 2.03).
What is the liquidity of UCB PHARMA AS like?
The current ratio was 1.33 in 2025 (median 1.38).
How does UCB PHARMA AS compare in Handel?
UCB PHARMA AS ranks 23,328 of 38,670 in Handel for 2025. Among companies of the same size (medium-sized companies) it ranks 1,336 of 2,203. Revenue changed by 5.9% from the year before.
From the Central Coordinating Register
- Org. no.
- 976281918
- Legal form
- AS
- Sector
- Handel (46.460)
- Size tier
- medium
- Employees
- 5 registered 12 May 2025
- Founded
- 20 March 1996 30 years in operation
- Share capital
- 0.49 MNOK
- Business address
- Haakon VIIs gate 6, 0161 OSLO
- Municipality
- Oslo rank 63–221 of 357 in Norway
- Latest accounts filed
- 2025
Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre
Ownership and roles
- Chief executive
- Fredrik Arneberg
- Chair of the board
- Christina Dyreborg Jeppesen
- Board member
- Jaana Mattila
- Board member
- Fredrik Arneberg
- Auditor
- FORVIS MAZARS AS
- Accountant
- KPMG ACCOUNTING AS
- Accountant
- AZETS INSIGHT AS
Source: Central Coordinating Register, fetched 29 October 2026. Only names are shown.
Owners and shareholdings will appear here once the shareholder data extract is in place.
Coming · not built yet
Error in the data?
Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.
Figures last fetched 28 October 2026.
Year by year · 2023–2025
| Key figure | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|
| Index | 39 | 51 | 45 | |
| Rank | 23,145 | 18,153 | 23,328 | |
| Operating margin | 3.3% | 3.4% | 3.3% | |
| Return on assets | 6.2% | 7.1% | 6.0% | |
| Equity ratio | 22.3% | 28.7% | 24.8% | |
| Current ratio | 1.28 | 1.40 | 1.33 | |
| Revenue growth | – | 9.3% | 5.9% |
Accounts
From the Brønnøysund Register Centre, in the company's reporting currency (NOK).
| Key figure | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating revenue | 227.5 MNOK | 248.6 MNOK | 263.4 MNOK |
| Operating profit | 7.5 MNOK | 8.5 MNOK | 8.7 MNOK |
| Profit before tax | 5.9 MNOK | 5.4 MNOK | 5.1 MNOK |
| Net profit | 4.4 MNOK | 3.6 MNOK | 4.0 MNOK |
| Financial expenses | 3.2 MNOK | 4.0 MNOK | 5.0 MNOK |
| Total assets | 148.8 MNOK | 132.8 MNOK | 167.3 MNOK |
| Current assets | 148.6 MNOK | 132.7 MNOK | 167.3 MNOK |
| Equity | 33.1 MNOK | 38.1 MNOK | 41.4 MNOK |
| Retained earnings | 27.9 MNOK | 31.6 MNOK | 35.5 MNOK |
| Total liabilities | 115.6 MNOK | 94.7 MNOK | 125.9 MNOK |
| Current liabilities | 115.6 MNOK | 94.7 MNOK | 125.9 MNOK |
Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 28 October 2026, accounts id 6747772.
Further
Similar companies
- FOTOKNUDSEN AS index 45, rank 23,289 · compare
- G. COWARD AS index 45, rank 23,297 · compare
- BRI AGRI AS index 45, rank 23,309 · compare
- MØLLER SPORTSBILER GARDERMOEN AS index 45, rank 23,322 · compare
- SALTO SYSTEMS AS index 45, rank 23,333 · compare